At least another year of waiting...I love how Paul on the conference call made it sound like a victory of how well the company has crawled out of the deficit of a hole they got themselves into after making financial and operational mistakes. It's hard not to be completely pessimistic. Basically all I took away was that they finally got their spending under control and have flat expectations for the future without something good coming out of oncology. That, and we'll be waiting until the end of 2024 on TH-1902, so still dead money for longer.